



**Product Name:** OptiLeukin™ 2

**Product Number:** 555OLK0070

**Format:** Lyophilized Powder

**Product Description:** Recombinant Human Interleukin 2, Animal-Origin-Free

## CONTENTS

1. Product Description
2. Reconstitution Instructions
3. Handling & Storage
4. Concentration Range
5. Sterility & Filtration
6. Application-Specific Notes
7. Regulatory Notes
8. Additional Resources

## 1. Product Description

OptiLeukin 2 is a high-purity, recombinant human interleukin-2 (rhIL-2) manufactured using a chemically defined, animal- and bacteria-free platform. Designed to minimize regulatory burden and simplify raw material qualification, it offers consistent bioactivity and lot-to-lot performance for immune cell expansion workflows. OptiLeukin 2 is ideal for GMP-compliant cell therapy, biomanufacturing, and immunotherapy development.

## 2. Reconstitution Instructions

1. Reconstitute lyophilized OptiLeukin 2 in sterile, cell culture-grade water to a final concentration of 100 µg/mL.
2. Mix gently by triturating—avoid forming foam or bubbles; **do not vortex**.
3. Allow full dissolution (2–5 minutes) and visually confirm that no powder remains in solution



# Guidelines for Use

## 3. Handling & Storage

- Store lyophilized powder at 4°C, –20°C, or –80°C for up to 6 months, protected from light.
- Once reconstituted, aliquot and store at 4°C for up to 1 month or at –20°C or –80°C for up to 6 months.
- Avoid repeated freeze-thaw cycles.
- Do not expose to room temperature for extended periods post-reconstitution.

## 4. Suggested Concentration Range

- Adjust final concentration based on protocol and cell type requirements.

Cell Type	Low	High
Pan T Cells	100 IU/mL	300 IU/mL
T regs	100 IU/mL	300 IU/mL
γδ T cells	100 IU/mL	200 IU/mL
NK cells	400 IU/mL	600 IU/mL
TILs	6,000 IU/mL	7,000 IU/mL

## 5. Sterility & Filtration

- OptiLeukin 2 is 0.2 μm sterile filtered prior to lyophilization.
- Prepared in a chemically defined formulation suitable for cell culture applications.
- As with all cell therapy reagents, use aseptic technique and good laboratory practices when handling or preparing for use.

## 6. Application-Specific Notes

- Supports ex vivo expansion of T cells, Tregs, TILs, γδ T cells, and NK cells for use in advanced immunotherapy and cell therapy platforms.
- Compatible with serum-free, chemically defined systems across research and GMP workflows.
- Used in cell therapy, immune cell manufacturing, and iPSC-derived immune platforms.
- Scalable, regulatory-friendly alternative to E. coli– and HEK-derived IL-2.
- Designed for performance, reproducibility, and compliance in clinical and commercial biomanufacturing environments.

## 7. Regulatory Notes

- Animal-Origin-Free (AOF)
- Bacteria-Free
- Chemically Defined
- No adventitious virus or retrovirus testing required
- Reduced validation burden vs. E. coli– and HEK-derived IL-2
- Manufactured in cGMP Compliant, ISO 9001 Certified Facility
- Made in the USA

## 8. Additional Resources

- OptiLeukin 2 SDS
- OptiLeukin 2 Data Sheet
- OptiLeukin 2 Product Page

Copyright© 2025 InVitria, Inc. All rights reserved.

Reproduction or distribution of any InVitria materials, in whole or in part, is prohibited without prior written consent. All logos, names, designs, and marks displayed, including InVitria®, OptiLeukin™, and the InVitria® brand design, are trademarks or service marks owned or licensed by InVitria, Inc., Kansas, USA, unless otherwise noted. For details on InVitria's registered intellectual property, patents, and additional terms and conditions, please visit [www.InVitria.com/terms](http://www.InVitria.com/terms).